Lomond Therapeutics Holdings, Inc.
Clinical trials sponsored by Lomond Therapeutics Holdings, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to tackle tough leukemia Results expected Dec 2026 (estimated)
-
First step for new AML drug: safety check in healthy volunteers
Knowledge-focused CompletedThis study tested a new drug called ZE46-0134 in 112 healthy adults to see if it is safe and how the body handles it. The drug is being developed for a type of blood cancer called AML. Since this was the first time the drug was given to people, the main goal was to check for side…
Phase 1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New drug ZE50-0134 passes first safety check in healthy people
Knowledge-focused CompletedThis was a first-in-human study to see if ZE50-0134 is safe and how it behaves in the body. 104 healthy adults received either the drug or a placebo. The study also looked at how the drug interacts with other medications like rabeprazole and itraconazole. Since this was only in h…
Phase 1 • Sponsor: Lomond Therapeutics Holdings, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC